Wednesday 24 February 2016

Adoption Trends in Personal Cloud By Enterprises-large and small-to boost the global personal cloud market

Enterprise data clouds are fast emerging. Managers are set to transform digital workplace by making continual innovations in end-user computing as personal cloud intersect with many levels of setting up IT goal of enterprises. The degree of impact personal cloud is making on enterprises adoption of cloud services is driven to a large extent by the launch of unprecedented technologies like advanced sensors, Windows 10, smart wearables which is fast blurring the boundaries between consumer and enterprise computing. Increased access to a host of personal information and enhance intelligence is fast changing the technology landscape in personal cloud services.

https://www.alliedmarketresearch.com/personal-cloud-market

Wednesday 10 February 2016

Technological advancements in catheters devices & cost-effectiveness to boost the market growth

You must have come across urethral catheterization as a routine medical procedure which facilitates direct drainage of the urinary bladder from the bladder into a bag along a tube or continuous pipe. Painful as it may seem, this procedure is essential for patients across all groups, mostly to help them to relieve urine because of their inability to pee. Known as urinary catheter, it is a type of medical catheter, used for different diagnostic purposes or to serve various therapeutic ends such as to relieve urinary retention, instill medication, or provide irrigation. Medical catheters are tubes–of varying diameter and flexibility–used in healthcare to deliver medications, fluids or gases to patients and to drain bodily fluids such as urine. They may be made up of plastic, silicon rubber, PVC and nylon and includes neurovascular Catheters, intravenous catheters, urinary catheters and chest drainage tubes. Of these, silicone is the most commonly chosen material due to its inertness as it does not react with body fluids.

Catheterization is considered as a primary co-procedure along with other medical procedures such as angioplasty, cardiac electrophysiology, and neurosurgery and others. Increasing cardiovascular diseases and rising demand for minimal invasive surgeries, the rising incidence of diabetes, urinary bladder failure, kidney failures along with major technological enhancements in the equipment which can relief pain are the factors that will foster the growth of the market. 

Technical advancements and other developments in the technology used to insert these catheters may be useful in instances of long-term administration of medications such as antibiotics in patients. Or, simply such enhancements in designing equipment may be popular driven by relieving pain in patients. A recent development earlier this year shows the adductor canal catheter has claimed to lower pain among patients following total knee arthroplasty (TKA). This has been confirmed through the results conducted by researchers from Philadelphia's Thomas Jefferson University hospital.

Companies manufacturing tubing used in catheter develop innovative evolving requirements of medical catheters and devices to keep up with evolving trends of medical catheters and devices. Putnam Plastics Corp. Dayville, Conn., pioneering in extrusion technologies for medical catheters and devices, has developed an advanced tri-layer tubing technology with improved tensile and burst strength, with reduced elongation properties. The new Super-Tri tubing helps in the prevention of wire lock-up in catheters which involves guidewires. The tubing utilizes the material combination similar to traditional tri-layer tubing while offering superior performance characteristics. The tri-layer tubing is mostly used in PTCA (percutaneous transluminal coronary angioplasty) delivery systems and involves a HDPE inner layer for lubricity, thus providing a unique combination of strength, bondability and trackability.

 Another Ohio-based manufacturer PercuVision LLC that deals mostly with developing high-end urinary catheters claimed it has sold its visually guided catheter-placement system to as many as 20 smaller rural hospitals over the past two years since it received federal approval to market the equipment. Since then, the company is also engaged in developing advanced versions for other medical procedures, such as inserting a feeding tube through the nose that may be camera-equipped. The company opines that offering visually guided camera-equipped catheter will lead to less complication and cost savings. Led by such developments, the opportunities for catheters market. As per a recent report by Allied Market Research, the market would reach $42.5 billion by 2020, registering CAGR of 7.5% during the forecast period of 2014-2020.

Thursday 4 February 2016

Incandescent Light Bulb Getting Resurrected: A Recent MIT Research Suggests

Can government laws and bureaucratic set-up predict what free scientific and technological progress can or cannot achieve? The recent Wikipedia page titled “Phase-out of incandescent light bulbs” seems to suggest so. But why only Wikipedia: a plethora of recent media reports point to this direction that reiterates on the “death” of these bulbs, banned by governments in developed nations and discouraged by others. Many phase-out regulations that is being talked about in these reports relate to ban in the manufacture, importation or sale of incandescent light bulbs for general lighting purposes. As per a recent phasing out effort by EU, halogen bulbs have been phased out, and any bulb available for purchase after the 2016 date must have at least a B energy rating and these are to be replaced by Compact fluorescent lamps (CFL) and Light-emitting diode lamps (LEDs). Most European countries such as Brazil, Venezuela and Australia have already introduced a phase-out or ban. The reasons cited are attaining energy efficiency in general in all its electric components such as televisions & washing machines to tiniest motors and achieving a bigger goal E.U. goal of cutting greenhouse gas emissions by 20 % by 2020. They also put forth the argument that no noticeable improvement in incandescent efficiency in the last 10 years.

However, the recent claim by a team of researchers at MIT point otherwise. The incandescent bulb is being resurrected! Incandescent light bulbs works by the conversion of the electric current to heat energy which gets converted to light in the form of electromagnetic radiation. The emitted light contains the waves of all frequencies, especially those within the interval of the visible spectrum. Some of the frequencies are "not relevant" like the infrared waves and do not contribute our visibility. So, more than 95 % of the energy that goes into them is wasted, most of it as heat energy. Now researchers at MIT and Purdue University have decided to circumvent this problem.

New data center cooling systems to focus on energy efficiency

Data centers is a centralised facility for an organization’s IT operations and equipment where it stores, manages and disseminated its data and information concerning the functioning of the daily operations of the organisation or any particular business process. Data centers consist of network’s most critical systems and it is crucial that these data centers must remain cool so that the processors can function effectively and efficiently. To achieve this purpose of cooling, there must be a provision for effective data centers cooling system which would prevent the loss of data and discontinued flow of information thereby hindering the day to day business operations.

The exponential growth of data both structured and unstructured along with the continuing adoption for cloud computing is a key factor driving the demand for setting massive data centers. This would obviously require efficient and power-friendly data center cooling systems. Over the decade, there has been innovation in data center cooling, with large operators trying to achieve energy efficiency in their design of data center cooling systems.

Tuesday 2 February 2016

Biomaterials (Bio Implants) Market - Market Dynamics, Opportunities & Forecasts.

Allied Market Research has recently introduced a report titled “Biomaterials (Bio Implants) Market - Opportunities and Forecasts, 2014 -2020”. The report offers an in-depth insight into key drivers and restraining factors, market challenges, key segmentation on the basis of materials, application across geographies along with the profile of key market players.

Biomaterials are natural materials which are artificially derived and have large medical applications for the purpose of organ transplantation and replacement of tissues. The report highlights how the market for medical devices which accounted $240 billion in 2013 point to huge growth prospects of the bio-implants market. Increasing count of aging population across the world is a key driver for biomaterial market driven by increased applications of biomaterial is increasingly being used in wound healing, surgery, dental implants, neurology and tissue engineering. As per an estimate by the Society for Biomaterials, over 5000 novel research article are published every year for newer and innovative wound care techniques and surgical devices. 

The report takes into account the potential growth opportunities of the key segments, impact analysis of top impacting factors, Porter’s Five Forces Analysis along with identifying top investment pockets using the strategic tool such as GE9 cell matrix analysis. The report offers key developmental strategies adopted by key market players which would provide in-depth understanding of potential opportunities and market challenges faced by prominent companies. The analysis is expected to offer an unbiased assessment of industry value chain and factors that will create potential growth prospects for top companies. 

This report considers the competitive analysis of key market players. Top companies have collaborated to consolidate their positions in biomaterial market. For instance, Wright Medical Group recently completes the acquisition of BioMimetic Therapeutics Inc. which will help Wright’s Extermities business to expand its product portfolio by taking advantage of BioMimetic's cutting-edge biologics platform.

The report is aimed to key audiences such as medical device manufacturing companies, pharmaceutical companies, R&D institutes and academic institutes and other interested stakeholders.



Monday 1 February 2016

Regenerative Medicine explore new therapies using stem cells research & nanotechnology

Regenerative medicines and associated therapies can help mammalian cells to reconstruct: reconstruction of lost limbs, human cells, tissues and tendons, or even undo organ problems. Regenerative medicines have emerged as a promising field of tissue engineering and refers to the practice of providing treatments to repair, regenerate, and replace damaged cells and tissue. The numerous applications include offering therapies for complex diseases such as Alzheimers and spinal injuries or providing cures for chronic ones like cancer and diabetes. The trend of restoring damaged tissues is evident in spray-on skin and lab-grown ears, with the terms tissue engineering and regenerative medicine used interchangeably.



The benefits of regenerative medicines seemingly extend over medical applications to non-therapeutic ones such as biosensors which are employed to detect biological or chemical threat agents, or biomaterial chips that can assess the toxic effects of a medication. One of the main goals of this emerging field is to improve people’s quality of life and restoring them back to a normal functional state.

Researchers world have already been experimenting with stem cells for long. These progenitor cells can develop into several types of tissue, thereby driving the bodies to heal themselves. Some of the early and most promising clinical trials involved treating congestive heart diseases and regrowing muscles in soldiers who were severely wounded in war. Advances in stem cells especially related to pluripotent cells to treat various regenerative disorders focuses on stem cells that can turn into any kind of cell and is a key factor triggering the growth of the regenerative medicines market.

See related Press Release: http://goo.gl/aHFjeB

Regenerative medicines evolving as a multidisciplinary field of biomaterials incorporates nanotechnology as a potent tool to produce material structures that mimic the biological ones capable of providing very efficient delivery systems. The fabrication of materials, such as nanoparticles and scaffolds used for tissue engineering, and the nanopatterning of surfaces can help get “in vivo” in response to the biological signals mammalian cells receive from the surroundings. The applications of stem cells to harness the power of regenerative medicines for curing diseases such as frontotemporal dementia and amyotrophic lateral sclerosis (ALS) look for collaborative findings to help researchers to discover new approaches. Last month, two collaborative teams within USC Stem Cell bagged an award Audrey E. Streedain Regenerative Medicine Initiative Awards. The magnanimous award which summed up to $140,000 each support faculty members affiliated to USC who is keen on multi-investigator research collaborations with the goal of curing diseases using stem cells as potent tools. The eminent researchers Justin Ichida and Paula Cannon, with Department of Stem Cell Biology and Regenerative Medicine, aim to develop a powerful technique for which can help to rectify a gene mutation responsible for 10 % of all cases of ALS & frontotemporal dementia . According to Cannon “These grants are pretty unique in that they allow the type of high-risk research that isn’t feasible without collaboration,”

Various alliances have cropped up recently this year that hope to the bridge the gap between the academia and industry so that the ongoing R&D activities can translate to effective patient care using regenerative medicine. 

The Rare Disease Clinical and Patient Education Roundtable which took place on  27th January in Washington is focused on educating multi-sector stakeholders regarding the growth prospects of regenerative medicine market and large scale applications to cure various rare diseases. The event, first of its kind, is announced by the Alliance for Regenerative Medicine (ARM), an international organization representing the researches on gene therapy, cell therapy and tissue engineering. Such collaborations and joint events will tend to increase in future, as the technology progresses and results of cutting-edge research and clinical trials are made public. No doubt, dominant strategy adopted by companies is approval required to initiate clinical trials, continuation of trials and for the commercialization of these therapies. As per a recent report by Allied Market Research gene therapies are expected to be the fastest emerging technology, growing at a CAGR of 28.6% during 2014-2020 forecast period.